Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Integrated Cancer Services in Thailand: A Prototype for Excellence (CEICS)

14 maggio 2026 aggiornato da: Saengrawee Thanthong, Chulabhorn Cancer Center

Development and Implementation of a Prototype Centre of Excellence in Integrated Cancer Services in Thailand: A Feasibility Study

Cancer is a significant health crisis globally and specifically within Thailand, where it affects more than 122,000 individuals every year and leads to approximately 86,000 deaths. Beyond the physical and emotional toll on patients, the disease creates immense social and economic challenges.

In Thailand, cancer treatment costs exceed 26 billion baht (about $800 million USD) annually. Families often face out-of-pocket costs for cancer care that exceed 30% to 40% of their total household income. Furthermore, the aging of Thai society and lifestyle changes-such as "Westernized" diets and sedentary behavior-are expected to drive these numbers even higher. This situation has created an urgent need for new healthcare models that reduce the burden on major hospitals and make care more accessible to the public. The Project Goal: A new model of care to address these challenges: Researchers developed a prototype Center of Excellence in Integrated Cancer Services. The goal was to test whether a specialized cancer unit could be successfully integrated into a local community clinic rather than functioning as a large, separate hospital.

The study used Donabedian's model to evaluate quality, focusing on three specific areas: Structure: The physical setting, equipment, and staff. Process: How the services are actually delivered and Outcomes: The results of the care and the satisfaction of those involved. Phase of Development and Implementation The project was a three-year initiative funded by the National Science, Research, and Innovation Fund of Thailand. Phase 1: Focused on the conceptual design of the center. Phase 2: Involved detailed planning and the development of digital information systems. This is at Phase 3: Focused on the actual implementation and testing of the prototype center in Bangkok

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Services Provided to the Community The center followed Thailand's national "7-branch" Cancer Service Plan, focusing specifically on the first two foundational branches for this pilot phase :Cancer Prevention and Risk Reduction: Counseling on healthy lifestyle modifications. Programs to reduce tobacco and alcohol use. Education regarding the HPV vaccine. General health literacy promotion to help people understand their risks. Cancer Screening and Early Detection: Clinical breast exams to check for abnormalities. Cervical cancer screening. Colorectal cancer screening. Risk assessments and established protocols to refer patients to major hospitals if abnormalities were found.

The other five branches-diagnosis, treatment, palliative care, informatics, and research-were supported through integrated referral pathways rather than being performed directly at the community unit.

Digital Innovation and Technology: A key feature of the center was the use of health information technology to bridge the gap between patients and providers. These tools included: Mobile Health Applications: Used for tracking symptoms and providing educational outreach. Electronic Health Records (EHRs): Facilitated real-time data sharing among the care team.

Virtual Consultations: Allowed for remote support and counseling. Artificial Intelligence (AI): The center planned for future integration of AI to assist in more accurate and efficient cancer screening

Tipo di studio

Interventistico

Iscrizione (Effettivo)

358

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Tailandia
      • Bangkok, Tailandia, 10210
        • Princess Agrarajakumari Faculty of Nursing, Chulabhorn Royal Academy

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Inclusion Criteria:

  • Group 1: Service Recipients

This group included patients and their family members who received services at the prototype center. The criteria for inclusion were the following:

Age: Must be 20 years or older. Capacity: Must be able to express their opinions regarding the comprehensive cancer services.

Consent: Must be willing to participate in the research study. Group 2: Service Providers

This group consisted of 30 healthcare professionals (such as physicians, nurses, and pharmacists) directly involved in delivering care. The criteria for inclusion were:

,Age and Sex: Must be at least 20 years old; there were no restrictions regarding sex.

Professional Status: Must be actively providing services at the Comprehensive Cancer Centre of Excellence or its affiliated network facilities.

Knowledge Base: Must possess specific knowledge of the center's administrative and service systems.

Consent: Must express a willingness to participate in the study. Group 3: Cancer Care Experts

This group included 15 experts (administrators, academics, and researchers) who provided qualitative evaluation. The criteria for inclusion were:

Professional Experience: Must have a minimum of five years of experience in the field of cancer care.

Expertise: Must have the ability to provide deep insights into comprehensive cancer services.

Consent: Must be willing to participate in the research. Note: There were no restrictions regarding the sex or age of these experts.

Exclusion Criteria:

  • Group 1 (Service Recipients): Participants were required to be at least 20 years old, have the ability to express their opinions regarding the center's services, and be willing to participate in the study.

Group 2 (Service Providers): Eligible healthcare professionals had to be at least 20 years old, be actively providing services at the prototype center or its affiliated facilities, and possess specific knowledge of the center's administrative and service systems.

Group 3 (Cancer Care Experts): These individuals were required to have a minimum of five years of experience in cancer care and the capacity to provide deep insights into comprehensive cancer services. The sources note there were no restrictions regarding the sex or age of these experts

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Prototype Centre of Excellence in Integrated Cancer Services

The intervention, as a pilot unit, was established within the Warm Community Nurse Clinic to deliver community-based cancer prevention and screening services

. It highlights the model's core purpose as an integrated healthcare hub designed to test the feasibility of scaling such centres nationwide in Thailand
Altro: Health Service Delivery Model
The intervention in this study is the development and implementation of a prototype Centre of Excellence (COE) in Integrated Cancer Services in Bangkok, Thailand. This model is fundamentally distinguished by its integration into a local community setting-specifically established within the Warm Community Nurse Clinic-rather than functioning as a standalone, large-scale hospital. By leveraging the community's existing familiarity with the clinic, the intervention aims to improve accessibility and trust while reducing the financial and logistical burdens typically associated with seeking cancer care at major medical centers.
Altri nomi:
  • Lak Si is Alert to Fight Cancer

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Satisfaction Levels with Service Delivery
Lasso di tempo: Data was collected over the 12-month implementation period of Phase 3, from October 2023 to September 2024
Satisfaction is measured across three domains: Structure (the physical setting and resources), Process (the delivery of care and communication), and Outcomes (the results and perceived benefits)
Data was collected over the 12-month implementation period of Phase 3, from October 2023 to September 2024

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Chulabhorn Cancer Center

Collaboratori

Chulabhorn Royal Academy

Investigatori

  • Investigatore principale: Vilaivan Thongcharoen, PhD, PAFN, CRA

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 marzo 2024

Completamento primario (Effettivo)

13 luglio 2024

Completamento dello studio (Effettivo)

13 luglio 2024

Date di iscrizione allo studio

Primo inviato

14 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

14 maggio 2026

Primo Inserito (Effettivo)

20 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 50182
  • 180873 (Altro numero di sovvenzione/finanziamento: Thailand Science Research and Innovation)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

According to the sources, the research was conducted with strict protocols to maintain participant confidentiality and anonymity, including the use of anonymous codes and secure data storage. Crucially, the study's ethical guidelines mandated that all data were to be destroyed one year after the completion of the study. While the manuscript specifies that all data supporting the findings are included within the article and its supplementary materials, the raw individual participant data (IPD) is not available for sharing to ensure the protection of participant privacy and to remain in compliance with the data management plan approved by the Human Research Ethics Committee of Chulabhorn Royal Academy.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Cancro

Prove cliniche su Health Service Delivery Model

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Congo, DR of

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi